1-Boc-4-(4-Bromopyrazol-1-yl) piperidines CAS 877399-50-3 Puritas ≥98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica 1-Boc-4-(4-Bromopyrazol-1-yl) piperidinis (CAS: 877399-50-3) cum qualitate media Crizotinib (CAS: 877399- 52-5).Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Crizotinib Mediis,Please contact: alvin@ruifuchem.com
| Nomen chemicum | 1-Boc-4-(4-Bromopyrazol-1-yl)piperidine |
| Synonyma | Crizotinib-D;tert-Butyl 4-(4-Bromopyrazol-1-yl) piperidine-1-Carboxylata;4-(4-Bromopyrazol-1-yl) piperidine-1-Carboxylic Acidum tert-Butyl Ester;1-tert-Butoxycarbonyl-4-(4-Bromopyrazol-1-yl)piperidine;1-(4-Boc-Piperidino) -4-Bromopyrazole;1-Boc-4-(4-Bromo-1-Pyrazolyl)piperidine;4-Bromo-1-(N-Boc-Piperidin-4-yl) 1H-Pyrazole;tert-butyl 4-(4-Bromo-1H-pyrazol-1-yl) piperidine-1-carboxylata;1-(4-Boc-1-Piperidinyl) -4-Bromopyrazole;Crizotinib Impurity 4 |
| Stock Status | In Stock, Commercial Productio |
| CAS Number | 877399-50-3 |
| Formulae hypotheticae | C13H20BrN3O2 |
| M. Pondus | 330.23 g/mol |
| Liquescens punctum | 77.0 ad 81.0℃ |
| Density | 1.43 |
| Solubilitas | Solutum in Methanol |
| COA & MSDS | Praesto |
| Origin | Shanghai, China |
| Categoria | Medium Crizotinib (CAS: 877399-52-5) |
| Brand | Ruifu Chemical |
| Items | Signa inspectionis | Proventus |
| Aspectus | Solidus albus | Solidus albus |
| Liquescens punctum | 77.0 ad 81.0℃ | Obsequitur |
| Aquae Caroli Fischer | <0.50% | 0.11% |
| Puritas / Analysis Methodus | ≥98.0% (HPLC) | 99.3% |
| 1H NMR Imaginum | Conformat ut Structure | Obsequitur |
| Mass | Conformat ut Structure | Obsequitur |
| conclusio | Productum probatum est & obsequitur datis specificationibus | |
Sarcina:Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in loco frigido, sicco (2~8℃) reponunt et a cellis bene ventilatis ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Periculosam symbola Xn - Noxia
Periculum Codes 22 - Noxia absorpta
1-Boc-4-(4-Bromopyrazol-1-yl)piperidines (CAS: 877399-50-3) adhibetur inter Crizotinib (CAS: 877399-52-5).Crizotinib (nomen artis Xalkori,) est anti-cancer medicamentum quod est ALK (lymphoma kinase anaplastic) et ROS1 (c-ros oncogene 1) inhibitor, probatus ad tractationem quarundam cellae non parvae pulmonis carcinomatis (NSCLC) in US et nonnullis aliis nationibus, et tentationes clinicae subeundae ad salutem et efficaciam inanaplasticam magnae cellae lymphoma, neuroblastoma, aliaeque solidae tumores in adultis et infantibus provectis.
Mense Augusto MMXI, Civitatibus Foederatis Americae FDA approbata Crizotinib (PF- 02341066) pro curatione lymphoma kinasi anaplasticae (ALK) ordinatae cancer pulmonis non-magnae cellae (NSCLC).Crizotinib est duplex ATP auctor inhibitor kinasium tyrosinae c-MET (Mesenchymal-epithelialis Transitionis Factor) kinasus (cellularis IC50=8 nM) et ALK (cellularis IC50=20 nM), quorum utrumque magni ponderis scuta pro chemotherapy cancro sunt.Cum Crizotinib probatum est propter selectivity versus alias kinases inventas enzyme IC50 habere intra 100-duplices multiplices c-MET pro 13 ex 120 kinasibus probatis.In cellulis pertentantibus, Crizotinib inventum est RON (recepteur d'origine nantais) kinase cum 10 duplici fenestra selectivity super c-MET.
